checkAd

     202  0 Kommentare Amylyx Pharmaceuticals Announces FDA Approval of RELYVRIO for the Treatment of ALS - Seite 4

    About RELYVRIO (previously known as AMX0035 in the U.S.)

    RELYVRIO (sodium phenylbutyrate and taurursodiol) is an oral, fixed-dose medication approved to treat amyotrophic lateral sclerosis (ALS) in adults in the U.S. and approved with conditions as ALBRIOZA for the treatment of ALS in Canada. Additionally, the European Medicines Agency (EMA) is reviewing the Company’s Marketing Authorisation Application for AMX0035 for the treatment of ALS in Europe. AMX0035 is being explored for the potential treatment of other neurodegenerative diseases.

    INDICATION AND IMPORTANT SAFETY INFORMATION FOR RELYVRIO (sodium phenylbutyrate/taurursodiol), for oral suspension

    INDICATION
    RELYVRIO is indicated for the treatment of amyotrophic lateral sclerosis (ALS) in adults.

    IMPORTANT SAFETY INFORMATION
    Before you receive RELYVRIO, tell your doctor about all of your medical conditions, including if you:

    • have pancreas, liver, or intestinal problems.
    • have heart failure, including congestive heart failure.
    • have high blood pressure.
    • have kidney problems.
    • are pregnant or plan to become pregnant. It is not known if RELYVRIO will harm your unborn baby.
    • are breastfeeding or plan to breastfeed. It is not known if RELYVRIO passes into your breast milk. You and your doctor should decide the best way to feed your baby.

    Tell your doctor about all the medicines you take, including prescription and over-the-counter medicines, vitamins, and herbal supplements and any taurursodiol products, such as tauroursodeoxycholic acid (TUDCA).

    RELYVRIO may affect the way other medicines work, and other medicines may affect how RELYVRIO works.

    Lesen Sie auch

    What are the possible side effects of RELYVRIO?
    RELYVRIO may cause serious side effects, including:

    • Changes in bile acid levels. RELYVRIO may increase bile acid levels and cause worsening diarrhea if you already have problems with your liver, bile ducts, or pancreas. Your doctor should monitor you for these side effects. Some disorders of the pancreas, bile ducts, or intestines may also make it harder to absorb RELYVRIO.
    • Salt (sodium) retention. RELYVRIO contains a high amount of salt. For people who are sensitive to salt intake, such as people with heart failure, high blood pressure, or kidney problems, limit the amount of salt you eat and drink. Talk to your doctor about the total amount of daily salt that is right for you. Your doctor will monitor you for signs and symptoms of salt retention during your treatment with RELYVRIO.

    The most common side effects of RELYVRIO include:

    Seite 4 von 6



    Business Wire (engl.)
    0 Follower
    Autor folgen

    Weitere Artikel des Autors


    Amylyx Pharmaceuticals Announces FDA Approval of RELYVRIO for the Treatment of ALS - Seite 4 Amylyx Pharmaceuticals, Inc. (NASDAQ: AMLX) (“Amylyx” or the “Company”) today announced that the U.S. Food and Drug Administration (FDA) has approved RELYVRIO (sodium phenylbutyrate and taurursodiol) for the treatment of adults with amyotrophic …